Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.

This study compared health-related quality of life (HRQoL) in patients with relapsed/refractory large B‑cell lymphoma...

Continue ReadingTisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.